Review



recombinant human il 37b  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems recombinant human il 37b
    Recombinant Human Il 37b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 206 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human il 37b/product/R&D Systems
    Average 96 stars, based on 206 article reviews
    recombinant human il 37b - by Bioz Stars, 2026-06
    96/100 stars

    Images



    Similar Products

    96
    R&D Systems recombinant human il 37b
    Recombinant Human Il 37b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human il 37b/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    recombinant human il 37b - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    93
    R&D Systems rhil 37
    Rhil 37, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rhil 37/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    rhil 37 - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant il 37 protein
    Recombinant Il 37 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant il 37 protein/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant il 37 protein - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    95
    ACROBiosystems recombinant human il 37b protein
    Recombinant Human Il 37b Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human il 37b protein/product/ACROBiosystems
    Average 95 stars, based on 1 article reviews
    recombinant human il 37b protein - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    92
    R&D Systems human il 37b il 1f7b
    Human Il 37b Il 1f7b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human il 37b il 1f7b/product/R&D Systems
    Average 92 stars, based on 1 article reviews
    human il 37b il 1f7b - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    96
    R&D Systems recombinant human il 37b rhil 37b
    Fig. 1 IL-37 treatment ameliorated EAE at both priming and ongoing phases. (A) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS (n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. (B-C) EAE mice were treated i.p. with 1 µg of <t>rhIL-37b/</t> day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) (B) and 26 days p.i. (chronic; n = 4 per group) (C), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant
    Recombinant Human Il 37b Rhil 37b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human il 37b rhil 37b/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    recombinant human il 37b rhil 37b - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 1 IL-37 treatment ameliorated EAE at both priming and ongoing phases. (A) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS (n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. (B-C) EAE mice were treated i.p. with 1 µg of rhIL-37b/ day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) (B) and 26 days p.i. (chronic; n = 4 per group) (C), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant

    Journal: Journal of neuroinflammation

    Article Title: IL-37 suppresses CNS autoimmunity by increasing the frequency of Treg cells and reducing CD4 + T cell-derived IL-10 production.

    doi: 10.1186/s12974-024-03295-1

    Figure Lengend Snippet: Fig. 1 IL-37 treatment ameliorated EAE at both priming and ongoing phases. (A) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS (n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. (B-C) EAE mice were treated i.p. with 1 µg of rhIL-37b/ day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) (B) and 26 days p.i. (chronic; n = 4 per group) (C), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant

    Article Snippet: Recombinant human IL-37b (rhIL-37b) (R&D Systems) was reconstituted in phosphate-buffered saline (PBS) at 200 μg/mL.

    Techniques: Control

    Fig. 2 IL-37 enhanced MBP expression. (A) The lumbar section of the spinal cord was harvested from EAE mice treated with PBS (left) or rhIL-37b (middle) at the peak of disease (n = 4 mice in each group). Naïve mice (right) are illustrated as a control to show healthy spinal cord. (B) Mean fluorescent inten sity of MBP expression in both groups was measured using FIJI software. Unpaired t-test was performed to analyze these two groups. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant

    Journal: Journal of neuroinflammation

    Article Title: IL-37 suppresses CNS autoimmunity by increasing the frequency of Treg cells and reducing CD4 + T cell-derived IL-10 production.

    doi: 10.1186/s12974-024-03295-1

    Figure Lengend Snippet: Fig. 2 IL-37 enhanced MBP expression. (A) The lumbar section of the spinal cord was harvested from EAE mice treated with PBS (left) or rhIL-37b (middle) at the peak of disease (n = 4 mice in each group). Naïve mice (right) are illustrated as a control to show healthy spinal cord. (B) Mean fluorescent inten sity of MBP expression in both groups was measured using FIJI software. Unpaired t-test was performed to analyze these two groups. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant

    Article Snippet: Recombinant human IL-37b (rhIL-37b) (R&D Systems) was reconstituted in phosphate-buffered saline (PBS) at 200 μg/mL.

    Techniques: Expressing, Control, Software